T he angiotensin II receptor blockers (ARBs) represent a newer class of antihypertensive agents. Their mechanism of action differs from that of the angiotensin-converting enzyme (ACE) inhibitors, which also affect the renin-angiotensin system. The ARBs were developed to overcome several of the deficiencies of ACE inhibitors: competitive inhibition of ACE results in a reactive increase in renin and angiotensin I levels, which may overcome the blockade effect; ACE is a relatively nonspecific enzyme that has substrates in addition to angiotensin I, including bradykinin and other tachykinins, and thus, inhibition of ACE may result in accumulation of these substrates; production of angiotensin II can
Metab indicates metabolite; bioavail, bioavailability.
occur through non-ACE pathways as well as through the primary ACE pathway, and these alternative pathways are unaffected by ACE inhibition; specific adverse effects are associated with ACE inhibitor effects on the enzyme; and ARBs may offer more complete angiotensin II inhibition by interacting selectively with the receptor site (1) . All 7 drugs in this class are approved by the Food and Drug Administration for the treatment of hypertension, either alone or in combination with other drugs. Unlabeled uses include the treatment of congestive heart failure and, for losartan and irbesartan, diabetic nephropathy (2, 3).
PHARMACOLOGY
The renin-angiotensin system, specifically angiotensin II, is implicated in the pathogenesis of essential hypertension, renovascular hypertension, congestive heart failure, and renal diseases associated with albuminuria (1, 4, 5) . Blockade of the reninangiotensin system with ACE inhibitors has provided effective treatment of these conditions; however, some of the adverse effects of ACE inhibitors appear to be unrelated to angiotensin II blockade. For example, cough and angioedema are due to other effects of ACE inhibition, such as degradation of bradykinins and prostaglandins (1) .
The ARBs' mechanism of action, selective inhibition of angiotensin II by competitive antagonism of the angiotensin II receptors, has been speculated to reduce adverse effects and possibly improve clinical efficacy. ARBs displace angiotensin II from the angiotensin I receptor and produce their blood pressure-A metaanalysis of 43 randomized clinical trials (in 11,281 patients) comparing ARBs with placebo, drugs in other antihypertensive classes, and other ARBs found comparable blood pressure reductions for all ARBs; response rates were 48% to 55% (1, 4) . The results of these trials suggest that candesartan, irbesartan, and telmisartan may be slightly more effective than losartan.
ADVERSE REACTIONS
In general, the ARBs are well tolerated. None of the drugs reviewed has a specific, dose-dependent adverse effect. Because cough is seen as a class effect of ACE inhibitors, studies with ARBs have specifically addressed this concern. The frequency of cough has been significantly lower in patients taking ARBs than in patients taking lisinopril (5) . Table 3 reviews the adverse reactions that have occurred in at least 2% of patients.
All of the ARBs are pregnancy category C for the first trimester and category D for the second and third trimesters.
DRUG INTERACTIONS
Comparison of the class as a whole reveals that losartan has the highest potential for drug interactions due to its involvement with the hepatic cytochrome P450 enzyme system (3). No sig- (7) Losartan 50 mg x 4 weeks, then 8 mg and losartan 50 mg were not significant. Candesartan 16 mg 100 mg x 4 weeks (115 patients) lowered systolic BP more effectively than either losartan dose Placebo (38 patients) (P < 0.05).
8-week double-blind, Irbesartan 300 mg (142 patients) Irbesartan 300 mg was superior to both irbesartan 150 mg and randomized, parallel (8) Irbesartan 150 mg (142 patients) losartan 100 mg in lowering sitting diastolic BP (P = 0.05). Losartan 100 mg (141 patients) Irbesartan 150 mg and losartan 100 mg did not differ in response. Placebo (142 patients)
Irbesartan was better tolerated than losartan.
6-week double-blind, Telmisartan 40 mg (57 patients) Telmisartan 40 mg and 80 mg had significantly greater reductions randomized (9) Telmisartan 80 mg (54 patients) of ambulatory BP assessment (from baseline) than losartan Losartan 50 mg (57 patients) (P < 0.05). † Telmisartan 80 mg had greater reductions in diastolic and systolic BP from baseline than losartan at all evaluation periods. were lower with valsartan (P < 0.01). Trough/peak ratio of BP was for 4 weeks followed by a significantly greater with valsartan (P < 0.05). (Both agents main-2-week washout (11) tained antihypertensive effects throughout the 24 hours.)
8-week randomized, doubleValsartan 80 mg x 4 weeks, then There was no significant difference between the 2 drug treatments. blind, placebo-controlled (12) 160 mg x 4 weeks (551 patients) Valsartan showed a slightly greater response rate at the end of 8 Losartan 50 mg x 4 weeks, then weeks (P < 0.021). 100 mg x 4 weeks (273 patients) 8-week double-blind, Olmesartan 20 mg (147 patients) Reduction of sitting diastolic BP with olmesartan was greater than randomized, parallel (13) Losartan 50 mg (150 patients) with losartan (P = 0.0002), valsartan (P < 0.0001), or irbesartan Valsartan 80 mg (145 patients) (P = 0.0412). Reductions of systolic BP were not significantly Irbesartan 150 mg (146 patients) different. Reduction in mean 24-hour diastolic and systolic BP with olmesartan was significantly greater than with losartan and valsartan (P ≤ 0.05).
Comparative trial ‡ Eprosartan 600 mg (60 patients) Mean change in BP was greater for eprosartan but did not reach Losartan 50 mg (60 patients) statistical significance.
*Response defined as a decrease in diastolic BP to <90 mm Hg or at least a decrease of 10 mm Hg. †Ambulatory blood pressure assessed continuously throughout the 18-to 24-hour period after dosing. ‡Personal communication, Maryann T. Travaglini, PharmD, SmithKline Beecham Pharmaceuticals, April 2, 1998.
BP indicates blood pressure.
nificant drug interactions involving valsartan, irbesartan, or candesartan have been reported. Olmesartan is not metabolized by the cytochrome P450 enzyme system reducing the risk of interactions with drugs metabolized by these enzymes (2). Table 4 summarizes significant drug interactions for this group of drugs.
SPECIAL PATIENT CONSIDERATIONS The elderly and patients with renal or hepatic impairment
There are no specific considerations for the ARBs in the elderly or patients with renal or hepatic impairment. As with ACE inhibitors, acute renal failure may occur if these agents are given to patients with renal artery stenosis. In patients with mild to moderate hypertension who took part in the clinical trials, kidney function was not adversely affected; even in the presence of chronic renal insufficiency, ARBs are generally well tolerated, presumably because they are largely cleared in the bile (1).
Patients with heart failure
Several large, ongoing trials have been designed to evaluate the effects that ARBs have on morbidity and mortality in cardiac disease, including heart failure. The goal is to define the role of ARBs in therapy and compare it to that of ACE inhibitors. The results from the ELITE II trial suggest that treatment with losartan (50 mg daily) is not superior to treatment with captopril (50 mg 3 times daily) but is significantly better tolerated (14) . Because the differences in morbidity or mortality rates associated with losartan and captopril are insignificant, losartan would be an appropriate choice for patients who are unable to tolerate ACE inhibitors (14) .
The Val-HeFT study results suggest that adding valsartan to an ACE inhibitor does not improve survival (14) . However, a subgroup analysis of patients not treated with an ACE inhibitor was performed which allowed comparison between valsartan (as monotherapy) and placebo. The results indicated reduced allcause mortality and all-cause hospitalization (14, 15) . This finding may well represent the strongest evidence to date that ARBs are comparable in efficacy to ACE inhibitors with regard to morbidity and mortality (14) . The Candesartan in Heart Failure to Affect Reduction in Morbidity and Mortality (CHARM) study has 3 arms: comparison of candesartan to placebo as add-on therapy to an ACE inhibitor; of candesartan to placebo in patients unable to tolerate ACE inhibitors; and of candesartan to placebo in patients with symptomatic heart failure with preserved systolic function (ejection fraction >40%) (14) . This study should be completed sometime in 2003 and will help better determine the role of ARBs as therapy in patients with heart failure.
DOSING AND ECONOMIC ISSUES
ARBs do not differ significantly in cost when prescribed once daily, as shown in Table 5 . Losartan, candesartan, and eprosartan may require twice-daily dosing in some patients because of their short half-lives. Twice-daily dosing may substantially increase cost.
SUMMARY
The ARBs have very similar clinical profiles. They do, however, have different pharmacokinetic profiles, which may lead to some differences in efficacy. The newer agents irbesartan, candesartan, telmisartan, and olmesartan have longer half-lives and durations of action than the older agents losartan and valsartan (5) . Twenty-four-hour blood pressure control could be more readily achievable with the newer agents. Losartan and valsartan may need to be administered twice daily in patients needing greater antihypertensive effects, whereas the agents with longer durations of action have no added benefit when administered 
*From references 2 and 3.
URTI indicates upper respiratory tract infection.
more than once daily. Of course, a once-daily product is always preferred. Several double-blind, head-to-head comparative trials have evaluated the relative antihypertensive efficacy of the ARBs in patients with mild to moderate hypertension. The net result is that the longer-acting agents may be more effective than losartan and valsartan at providing 24-hour blood pressure control. But, as also mentioned, a metaanalysis of 43 trials comparing the antihypertensive effects of ARBs found comparable antihypertensive efficacies within the ARB class (4, 5) . Whether reported differences in efficacy are clinically relevant regarding morbidity and mortality has not been determined.
When evaluating differences among the ARBs, their current and future places in therapy for unlabeled uses must be considered. ARBs have been evaluated for use in heart failure, as combination therapy with ACE inhibitors and alone as standard therapy. Losartan and valsartan are the only ARBs for which studies have been completed that involved long-term follow-up with morbidity and mortality as endpoints. Neither agent can replace ACE inhibitors as first-line therapy, but both remain a rational alternative for patients unable to tolerate ACE inhibitors. Candesartan is currently being evaluated for this same use. 
